REG - Spectral MD Holdings - Change of Interim Results Date

Spectral MD HoldingsAnnouncement

12/09/2022 13:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220912:nRSL1416Za&default-theme=true

RNS Number : 1416Z  Spectral MD Holdings, Ltd.  12 September 2022

Spectral MD Holdings, Ltd

("Spectral MD" or the "Company")

 

Change of Interim Results Date

Investor Presentation

 

LONDON, U.K AND DALLAS, TX, U.S. Spectral MD Holdings, Ltd. (AIM: SMD), a
predictive analytics company with proprietary AI and optical technology for
faster and more accurate treatment decisions in wound care, announces that it
will now release its interim results for the six months ended 30 June 2022 on
Tuesday 20 September 2022.

 

Investor presentation

 

Wensheng Fan, Chief Executive Officer, and Nils Windler, Chief Financial
Officer, will provide a live presentation relating to the interim results via
the Investor Meet Company platform on Tuesday 20 September 2022 at 4.30 pm
BST.

 

The presentation is open to all existing and potential investors. Questions
can be submitted pre-event via your Investor Meet Company dashboard up until
9.00 am BST the day before the meeting or at any time during the live
presentation. Investors can sign up to Investor Meet Company for free and add
to meet Spectral MD here
(https://www.investormeetcompany.com/spectral-md-holdings-ltd/register-investor)
.

 

Investors who already follow Spectral MD on the Investor Meet Company platform
will automatically be invited.

 

For further information please contact:

 

 Spectral MD Holdings, Ltd.                                                      investors.spectralmd.com
 Wensheng Fan, Chief Executive Officer                                           via Walbrook PR
 Nils Windler, Chief Financial Officer

 SP Angel Corporate Finance LLP (NOMAD and Joint Broker)                         Tel: +44 (0)20 3470 0470
 Stuart Gledhill/Caroline Rowe (Corporate Finance)

 Vadim Alexandre/Rob Rees (Sales & Broking)

 Stifel Nicolaus Europe Limited (Joint Broker)                                   Tel: +44 (0)20 7710 7600

 Charles Hoare / Ben Maddison / Nick Harland /

 Will Palmer-Brown

 Walbrook PR Ltd (Media & Investor Relations)      Tel: +44 (0)20 7933 8780 or spectralMD@walbrookpr.com
 Paul McManus / Louis Ashe-Jepson                  Mob: +44 (0)7980 541 893 / +44 (0)7747 515 393

 Alice Woodings                                    +44 (0)7407 804 654

 

About Spectral MD:
 

We are a dedicated team of forward-thinkers striving to revolutionize the
management of wound care by "Seeing the Unknown" ® with our DeepView(®)
Wound Imaging System.

www.spectralmd.com

info@spectralmd.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NORLTMBTMTABBPT